Taiwan's disease profile will remain favourable for prescription drugs as the prevalence of chronic diseases continues to grow and authorities work to improve the drug approval process. This will cause a corresponding rise in demand for treatments in therapeutic areas such as cardiovascular diseases, oncology and dementia. A key risk facing multinational drugmakers seeking to commercialise products that target these disease groups will stem from the cost containment measures employed by the National Health Insurance Administration (NHIA). The Taiwanese pharmaceutical market amounted to TWD195bn (USD6.5bn) in 2018, accounting for 16.7% of total healthcare spending. It has one of the largest medicine market in the Asia Pacific, with a high per- capita pharmaceutical spending of around USD273 in the same year. As with most developed countries, prescription drugs are dominant in the market, accounting for 93% of total sales in 2018 - the bulk of which (around 70%) came from patented drugs with a value of TWN126bn (USD4.2bn).

Key View 

SWOT 

Industry Forecast 

Industry Risk/Reward Index 

Regulatory Development 

Market Overview 

Competitive Landscape 

Company Profile

Taiwan Demographic Outlook 

Pharmaceuticals & Healthcare Glossary 

Pharmaceuticals & Healthcare Methodology